| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30003686 | HIV | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
| TVIS30088900 | HIV | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
| TVIS30076730 | HIV | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
| TVIS30060933 | HIV | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
| TVIS30060934 | HIV | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
| TVIS20011880 | HPV | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
| TVIS20058749 | HPV | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
| TVIS44036219 | HTLV-1 | ENSG00000138735.16 | protein_coding | PDE5A | No | No | 8654 | G5E9C5 O76074 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | PDE5A |
|---|---|
| DrugBank ID | DB00862 |
| Drug Name | Vardenafil |
| Target ID | BE0000182 |
| UniProt ID | O76074 |
| Regulation Type | inhibitor |
| PubMed IDs | 16926278; 12625845; 11669467; 11890515; 14626653; 12955149; 17959709; 17979301 |
| Citations | Blount MA, Zoraghi R, Ke H, Bessay EP, Corbin JD, Francis SH: A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization. Mol Pharmacol. 2006 Nov;70(5):1822-31. Epub 2006 Aug 22.@@Carrier S: Pharmacology of phosphodiesterase 5 inhibitors. Can J Urol. 2003 Feb;10 Suppl 1:12-6.@@Kim NN, Huang YH, Goldstein I, Bischoff E, Traish AM: Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor. Life Sci. 2001 Sep 28;69(19):2249-56.@@Saenz de Tejada I, Angulo J, Cuevas P, Fernandez A, Moncada I, Allona A, Lledo E, Korschen HG, Niewohner U, Haning H, Pages E, Bischoff E: The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res. 2001 Oct;13(5):282-90.@@Scheen AJ: [Medication of the month. Vardenafil (Levitra)]. Rev Med Liege. 2003 Sep;58(9):576-9.@@Sung BJ, Hwang KY, Jeon YH, Lee JI, Heo YS, Kim JH, Moon J, Yoon JM, Hyun YL, Kim E, Eum SJ, Park SY, Lee JO, Lee TG, Ro S, Cho JM: Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature. 2003 Sep 4;425(6953):98-102.@@Wang H, Ye M, Robinson H, Francis SH, Ke H: Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Mol Pharmacol. 2008 Jan;73(1):104-10. Epub 2007 Oct 24.@@Zoraghi R, Francis SH, Corbin JD: Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors. Biochemistry. 2007 Nov 27;46(47):13554-63. Epub 2007 Nov 3. |
| Groups | Approved |
| Direct Classification | Benzenesulfonamides |
| SMILES | CCCC1=NC(C)=C2N1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(CC)CC1 |
| Pathways | |
| PharmGKB | PA10229 |
| ChEMBL | CHEMBL1520 |
